FDA+ roundup: Flurry of guidance documents, updated risk criteria for Covid-19 mAbs, personnel moves and more
The FDA remains without a permanent commissioner but as acting commissioner Janet Woodcock told the Food and Drug Law Institute’s annual conference yesterday, nothing at the agency is slowing down as a result.
With the release of new guidance documents on master protocols and other drug development changes, as well as FDA staff moves, updates on who should receive Covid-19 mAb treatments, preparations for a big public meeting next month on financial transparency and efficiency, the agency has its hands full.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.